US, Japan duo win Nobel Medicine Prize for cancer therapy

October 1, 2018
James Allison of the US and Tasuku Honjo of Japan have won the 2018 Nobel Medicine Prize

Two immunologists, James Allison of the US and Tasuku Honjo of Japan, won the 2018 Nobel Medicine Prize for research into how the body's natural defences can fight cancer, the jury said on Monday.

Unlike more traditional forms of cancer treatment that directly target cancer cells—often with severe side-effects—Allison and Honjo figured out how to help the patient's own immune system tackle the cancer more quickly.

The pioneering discoveries led to treatments targeting proteins made by some immune system cells that act as a "brake" on the body's natural defences killing cancer cells.

The Nobel Assembly in Stockholm said the therapy "has now revolutionised cancer treatment and has fundamentally changed the way we view how cancer can be managed".

In 1995, Allison was one of two scientists to identify the CTLA-4 molecule as an inhibitory receptor on T-cells, a type of white blood cell that play a central role in the body's natural immunity to disease.

The 70-year-old, whose mother died of cancer when he was 10, "realised the potential of releasing the brake and thereby unleashing our immune cells to attack tumours," the Nobel jury said.

Around the same time, Honjo discovered a protein on immune cells, the ligand PD-1, and eventually realised that it also worked as a brake but in a different way.

'Honoured and humbled'

On the website of his University of Texas MD Anderson Cancer Center, Allison said he was "honoured and humbled to receive this prestigious recognition".

"I never dreamed my research would take the direction it has," he said.

"It's a great, emotional privilege to meet cancer patients who've been successfully treated with immune checkpoint blockade. They are living proof of the power of basic science, of following our urge to learn and to understand how things work."

Honjo, 76, meanwhile vowed to push ahead with his work.

"I want to continue my research... so that this immune therapy will save more cancer patients than ever," he told reporters at the University of Kyoto where he is based.

Scientists have attempted to engage the immune system in the fight against cancer for more than 100 years, but until the seminal discoveries by the two laureates, progress into clinical development was modest.

Antibodies against PD-1 have been approved by the US Food and Drug Administration as an investigational new drug and developed for the treatment of cancer.

Former US President Jimmy Carter, 94, a 2002 Nobel Peace Prize laureate, survived melanoma, a severe stage of skin cancer which spread to his brain, after undergoing a form of immunotherapy, among others.

Research by Allison's team has meanwhile led to the development of a monoclonal antibody drug, which was approved by the US Food and Drug Administration (FDA) in 2011 for the treatment of melanoma. It is known commercially as Yervoy.

"I'd like to just give a shout out to all the patients out there to let them know we are making progress now," Allison told a news conference in New York.

Allison and Honjo have previously shared the 2014 Tang Prize, touted as Asia's version of the Nobels, for their research.

New therapies 'desperately needed'

Other cancer treatments have previously been awarded Nobel prizes, including methods for hormone treatment for prostate cancer in 1966, chemotherapy in 1988 and bone marrow transplantation for leukaemia in 1990.

The Nobel Assembly said advanced cancer—the second biggest killer worldwide—remains immensely difficult to treat and novel therapeutic strategies are desperately needed.

The duo will share the Nobel prize sum of nine million Swedish kronor (about $1.01 million or 870,000 euros).

Monday's announcement was partially eclipsed by a Stockholm court's decision to sentence Frenchman Jean-Claude Arnault, a 72-year-old at the heart of a Nobel scandal, to two years in prison for rape that emerged during the #MeToo campaign.

The aftermath has led to a bitter internal dispute that has prevented the Academy from functioning properly, and as a result it postponed this year's Literature Prize until 2019—the first time the prize has been delayed since 1949.

The winners of this year's physics prize will be announced on Tuesday, followed by the chemistry prize on Wednesday. The peace prize will be announced on Friday, and the economics prize will wrap up the Nobel season on Monday, October 8.

Explore further: US, Japanese immunologists awarded Tang Prize for cancer quest

Related Stories

US, Japanese immunologists awarded Tang Prize for cancer quest

June 19, 2014
An American and a Japanese immunologist were Thursday named joint recipients of the Tang Prize, touted as Asia's version of the Nobels, for their contributions in the fight against cancer.

Nobel jury caught off guard by death of laureate

October 3, 2011
The Nobel Medicine Prize jury was caught off guard Monday when it honoured a Canadian scientist who unbeknownst to them died just days before the announcement, with prize rules forbidding posthumous awards.

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

Modest Nobel laureate says Japan deserves his prize

October 8, 2012
Japanese stem cell pioneer Shinya Yamanaka responded modestly after winning the Nobel prize for medicine Monday, saying his country really deserves the award.

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Breast cancer drug could create chink in the armour of pancreatic cancer

December 11, 2018
The well-known drug tamoxifen could exploit a weakness in the physical 'scaffolds' around tumours, according to research led by Imperial.

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

rrwillsj
not rated yet Oct 01, 2018
Anon, just another Artificial Stupid trolling for gullible desperate. Pulling them into it's programmer''s web to have their hopes crushed and their bank accounts drained.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.